Understanding How Alzheimer's Disease Impacts the Therapeutic Response to Transcranial Direct Current Stimulation (NCT05508841)
🩺 Plain-English Summary (8th-Grade Level)
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.
Who can join: Review the eligibility criteria below.
Location: Baycrest Health Sciences — Toronto, Ontario
Age range: 50 Years to 90 Years
🧪 Interventions in This Study
- tDCS and Cognitive Training (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Baycrest Health Sciences — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 725-2500
Email: troncero@research.baycrest.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease
- The Use of Memantine for Prevention of Alzheimer's Disease — Charlottesville, Virginia
- Investigation of Inflammation Using [C-11]-CS1P1 — St Louis, Missouri
- Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia — Palo Alto, California
- A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Gilbert, Arizona
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease — Cambridge, Massachusetts
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease — Phoenix, Arizona
Explore by condition: All Alzheimer Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.